ACTINIUM PHARMACEUTICALS, INC. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $17.90 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-15.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2019-03-15
- ACTINIUM PHARMACEUTICALS, INC. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2017 was $17.90M.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2017-12-31 | $17.90M 10-K · filed 2019-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |